肾透明细胞癌PDCD5表达及与预后的关系  

Relationship between programmed cell death 5 protein expression and prognosis of renal clear cell carcinoma

作　　者：谭万龙[1] 熊林[1] 郑少斌[1] 郁兆存[1] 齐桓[1] 杜跃军[1] 吴芃[1] 

机构地区：[1]南方医科大学南方医院泌尿外科,广东广州510515

出　　处：《南方医科大学学报》2006年第9期1316-1318,共3页Journal of Southern Medical University

基　　金：南方医院院长基金(20050006)

摘　　要：目的探讨PDCD5在肾透明细胞癌发生、发展中的作用及与预后关系。方法采用免疫组织化学方法,对46例肾透明细胞癌组织中PDCD5表达进行研究,对患者存活率进行回顾性随访。结果癌旁肾组织中PDCD5阳性表达率显著高于肾癌组织。PDCD5阳性表达率随肾透明细胞癌病理分级和临床分期的上升而下降,染色强度也减弱。PDCD5阳性表达组3年及5年存活率高于阴性表达组。结论PDCD5为肾透明细胞癌的负性调节因子,对抑制肾透明细胞癌的恶性转化和进展可能有重要的意义。Objective To study the role of programmed cell death 5 （PDCD5） protein in the oncogenesis and development of renal clear cell carcinoma and its association with the prognosis of the malignancy. Methods PDCD5 expression was assayed immunohistochemically in 46 cases of human renal clear cell carcinoma, and the patients＇ survival was followed up. Results PDCD5 staining in the adjacent normal tissue of the tumor was significantly stronger than that in the tumor tissue, and PDCD5 expression was significantly correlated with the tumor grade, stage and prognosis. The tumors of high grade with strong invasive ability had much less PDCD5 expression and lighter staining. The three-or five-year survival rates of patients positive for PDCD5 expression was much higher than that of patients negative for PDCD5 expression. Conclusion PDCD5 is a potent inhibitor of malignant transformation of renal clear cell carcinoma and may serve as a major predictor for evaluating the malignant potential and prognosis of the tumor.

关 键 词：肾透明细胞癌 PDCD5 TFAR19 

分 类 号：R737.11[医药卫生—肿瘤]